A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Esgliteo (Empagliflozin/Linagliptin, 10/5mg, 25/5mg) in Korean Patients With Type 2 Diabetes Mellitus
Latest Information Update: 07 Oct 2024
At a glance
- Drugs Empagliflozin/linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 23 May 2024 Status changed from active, no longer recruiting to completed.
- 19 Dec 2023 Planned End Date changed from 30 Nov 2023 to 30 Apr 2024.
- 19 Dec 2023 Planned primary completion date changed from 30 Nov 2023 to 30 Apr 2024.